期刊文献+

卵泡刺激素与高纯度尿促性腺激素联合方案在体外受精中有效性的评价 被引量:4

Evaluating the Efficacy of Mixed Protocol with FSH and Menopour in Women Undergoing in vitro Fertilization
原文传递
导出
摘要 在控制性促排卵(controlled ovarian stimulation,COS)中,促卵泡生成素(FSH)联合高纯度尿促性腺激素(HP-hMG)促排卵的理论基础是基于促黄体生成素(LH)具有协同FSH促进卵泡发育和卵子成熟的作用。COS通常采用促性腺激素释放激素激动剂(GnRH-a)或促性腺激素释放激素抑制剂(GnRH-A)抑制早发内源性LH峰,致内源性LH水平降低,尤其在卵泡发育中晚期随着颗粒细胞上LH受体增加,对生理性LH的需求也增加。因此,理论上COS中FSH促排卵同时配伍一定量的LH活性制剂(如:HP-hMG,商品名为贺美奇)可能有利于改善COS结局。但目前FSH联合hMG应用的报道并不多,从目前有限的数据显示FSH联合hMG的多样化配伍方案均可获得满意的临床结果,关键是需要针对每个个体制定个体化的COS方案。 Controlled ovarian stimulation(COS) protocols that use both hMG or HP-hMG and FSH known as "mixed protocols",are based on "two cells,two gonadotropins theory"which suggests that synergistic interaction of FSH and LH is crucial for appropriate folliculogenesis and oocyte maturation.The GnRH agonist(GnRHa) or GnRH antagonist(GnRH-A) employed in COS to suppress premature LH surge can reduce LH concentration.Whether it is necessary to LH supplementation during COS has remained controversial.Ovarian stimulation in IVF is successfully performed by using hMG or FSH preparations alone.The impact on IVF outcome of the different gonadotropin preparations such as hMG and FSH has been widely debated.In an attempt to improve IVF outcome,a lot of clinicians have employed that combine HP-hMG and FSH,so-called "mixed protocols".Recently,it is reported that FSH or HP-hMG alone protocols and mixed protocols with the different ratios of FSH∶HP-hMG administered have shown equally effective.The key point is to assess characteristics of individual women in order to determine in advance of an IVF attempt which COS protocol will produce the highest take-home baby rate.
作者 叶虹
出处 《生殖与避孕》 CAS CSCD 2012年第9期618-621,共4页 Reproduction and Contraception
关键词 高纯度尿促性腺激素(HP-hMG) 卵泡刺激素(FSH) 联合方案 highly purified hMG(HP-hMG); FSH; mixed protocols
  • 相关文献

参考文献12

  • 1Filicori M, Fazleabas AT, Huhtaniemi I, et al. Novol con- cepts of human chorionic gonadotropin: reproductive sys- tem interactions and potential in the management of infertility. Fertil Steril, 2005, 84(2):275-84.
  • 2Durnerin GI, Erb K, Fleming R, Hillier H, et al. Effects of recombinant LH treatment on folliculogenesis and respon- siveness to FSH stimulation. Hum Reprod, 2008, 23(2): 421-6.
  • 3叶虹,黄国宁,裴莉,陈春秀,刘红,刘东云.控制性超排卵中血清促黄体生成素浓度过低对体外受精-胚胎移植的影响[J].实用妇产科杂志,2002,18(3):154-157. 被引量:20
  • 4Wcstergaard LG, Laursen SB, Ande,'sen CY. Increased risk of early pregnancy loss by profound st, ppression of lt, tein- iziug hormone during ovarian stimulation in normogonado- trophic women unde,going assisted reproduction. Hum Reprod. 2000, 15(5): 1003-8.
  • 5Fleming R, Lloyd F, Herbert M, et al. Effects of protfound suppression of luteinizing hormone during ovarian stimu- lation on follicular activity, oocyte and embryos function in cycle somulated purified follicle stimulating hormone. Hum Reprod, 1998, 13(7): 1788-92.
  • 6van Wely M, Kwan I, Burt AL. et al. Recombinant versus urinary gonadotrophin for ovarian stimulation in assisted reproductive technology cycles. Cochrane Database Syst Rev, 2011, 16(2):CD005354.
  • 7Andersen AN, Devroey P, Arce JC, et al. Clinical outcome following stimulation with highly purified hMG or recom- binant FSH in patients undergoing IVF: a randomized as- sessor-blind controlled trial. Hum Reprod. 2006, 21(12): 3217-27.
  • 8Ye H, Huang GN, Pei L, et al. Outcome of in vitro fertilization following stimulation with highly purified hMG or recom- binant FSH in downregulated women of advanced repro- ductive age: a prospective, randomized and controlled trial. Gynecol Endocrinol, 2012, 28(7):540-4.
  • 9Melo M, Bellver J, Garrido N, et al. A prospective, randomized, controlled trial comparing three different gonodotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization. Fertil Steril, 2010, 94(3):958-64.
  • 10Keye WR Jr, Marrs RP, Check JH, et al. Evaluation of mixed protocols with Bravelle (human-derived FSH) and Repronex(hMG)to assess clinical efficacy (EMBRACE) in women undergoing in vitro fertilization. Fertil Steril, 2004, 82(2):348-57.

二级参考文献2

共引文献19

同被引文献55

  • 1黄荷风(主编).现代辅助生育技术.北京:人民军医出版社,2003:127.
  • 2罗丽兰.不孕与不育.2版.北京:人民卫生出版社,201l:521-528.
  • 3王秀芳.护理技术操作程序与质量管理标准.4版.杭州:浙江大学出版社,2009:76-77.
  • 4PeterRB,全松,陈雷宁.体外受精与辅助生殖-BournHall诊所临床实践与实验室操作指南_3版.北京:人民卫生出版社,2009:423;445-451.
  • 5Bosch E, Labarta E, Crespo J, et al. Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles. Hum Reprod, 2010, 25(8):2092-100.
  • 6Bosch E, Valencia I, Escudero E, et al. Premature luteinization during gonadotropin-releasing hormone antagonist cycles and its relationship with in vitro fertilization outcome. Fertil Steril, 2003, 80(6):1444-9.
  • 7Egbase PE, Al-Sharhan M, Grudzinskas JG. 'Early coasting' in patients with polycystic ovarian syndrome is consistent with good clinical outcome. Hum Reprod, 2002, 17(5): 1212-6.
  • 8Givens CR, Schriock ED, Dandekar PV, et al. Elevated serum progesterone levels on the day of human chorionic gonadot?ropin administration do not predict outcome in assisted re?production cycles. Fertil Steril, 1994,62(5):1011-7.
  • 9Van Vaerenbergh I, Fatemi HM, Blockeel C, et al. Progesterone rise on hCG day in GnRH antagonist/rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online, 2011,22(3):263-71.
  • 10Elnashar AM. Progesterone rise on the day ofhCG adminis?tration (premature luteinization) in IVF: an overdue update. J Assist Reprod Genet, 2010, 27(4):149-55.

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部